SCHEMBL29186556

SCHEMBL29186556

COc1cc(NC(C)=O)cc(Oc2ccnc3ccc(C(F)(F)F)cc23)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDR2 Q16832 2/20 0.77
▸ KDR P35968 12/20 0.51
▸ GAK O14976 3/20 0.51
▸ BRAF P15056 1/20 0.51
▸ MAPK14 Q16539 1/20 0.51
▸ TNNI3K Q59H18 1/20 0.51
▸ PDGFRA P16234 8/20 0.49
▸ MET P08581 3/20 0.48
▸ RIPK2 O43353 3/20 0.47
▸ NLK Q9UBE8 2/20 0.47
▸ ABL1 P00519 2/20 0.47
▸ LCK P06239 2/20 0.47
▸ EPHB6 O15197 1/20 0.47
▸ EPHA1 P21709 1/20 0.47
▸ EPHA8 P29322 1/20 0.47
▸ TXK P42681 1/20 0.47
▸ COQ8A Q8NI60 1/20 0.47
▸ EGFR P00533 2/20 0.46
▸ STK16 O75716 1/20 0.46
▸ AAK1 Q2M2I8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050292 0.87 DDR2 (0.83) DDR2KDRPDGFRAMETRIPK2
SCHEMBL29317854 0.87 DDR2 (0.83) DDR2KDRPDGFRAMETRIPK2
SCHEMBL29317847 0.87 DDR2 (1.00) DDR2KDRPDGFRAMET
SCHEMBL30050488 0.87 DDR2 (1.00) DDR2KDRPDGFRAMET
SCHEMBL29318211 0.85 DDR2 (0.83) DDR2KDRPDGFRAMETSRC
SCHEMBL29317860 0.84 DDR2 (0.82) DDR2KDRGAKPDGFRAMET
SCHEMBL30050295 0.84 DDR2 (0.82) DDR2KDRGAKPDGFRAMET
SCHEMBL29186589 0.84 DDR2 (0.82) DDR2KDRGAKPDGFRAMET
SCHEMBL30051291 0.84 DDR2 (0.82) DDR2KDRBRAFPDGFRAMET
SCHEMBL29186568 0.84 DDR2 (0.82) DDR2KDRBRAFPDGFRAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
CN-117321036-A phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity 成都安泰康赛生物科技有限公司 2023-12-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT DDR2 4341/4885KDR 4885/4885GAK 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback